Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Cutaneous Leishmaniasis Diagnosed by Press Imprint Smear

By LabMedica International staff writers
Posted on 28 Aug 2014
The diagnostic method of choice for cutaneous leishmaniasis historically has been microscopic demonstration of the parasite and isolation of the protozoa in culture and detection of parasite DNA by molecular diagnostic methods.

However most cases of cutaneous leishmaniasis occur in areas without good health infrastructure where diagnostic laboratory facilities are limited, therefore a rapid, sensitive, and inexpensive test for the diagnosis of the disease is needed for use in rural, resource-limited, endemic settings.

Scientists at the Federal University of Ceará (Fortaleza, Brazil) collected skin biopsy samples from 75 patients with a clinical diagnosis of cutaneous leishmaniasis, from September 2011 to August 2013. More...
Two biopsy samples were taken from the borders of ulcers (lesions) using a 3-mm disposable punch. One biopsy specimen was fixed in 10% formalin and processed for histopathology and the other specimen was used for a Press-Imprint-Smear.

For the imprint, the biopsy sample was put on a glass slide, and another glass slide was used to cover the tissue fragment sandwiched in between. On a firm surface, the tissue fragment between both glass slides was squeezed or squashed. Pressure on the middle of the slides was made, and therefore, the juice and tissue cells were spread on both slides surfaces that were in contact with the sample. Smears were air dried, fixed in methanol, stained with Giemsa, and examined microscopically using a 100 × oil immersion lens.

In 69 (92%) patients, the diagnosis of cutaneous leishmaniasis was confirmed by the identification of amastigotes by one or both methods. In 64 (85.3%) patients, amastigotes were detected by Press-Imprint-Smear. In 33 (44%) patients, amastigotes were detected by histopathology, and in 28 (37.3%) patients, amastigotes were detected by both methods. In 36 (48%) patients, parasites were seen only by Press-Imprint-Smear, and in five (6.7%) patients, parasites were seen only by histopathology. Leishmania (Viannia) braziliensis was the only species in this area.

The authors concluded that the Press-Imprint-Smear method was quicker that the histological method as it only took about an hour and had a much higher sensitivity of 85.3% compared with histology at 44%. Considering its sensitivity, low cost, and simplicity, Press-Imprint-Smear is a valuable tool for diagnosing cutaneous leishmaniasis and potentially, other infectious diseases at the point of care in rural or resource-limited endemic regions. The study was published on August 11, 2014, in the American Journal of Tropical Medicine and Hygiene.

Related Links:

Federal University of Ceará



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The approach uses in-house pathology tests and streamlined access to specialists to shorten the diagnostic pathway for children with immune conditions. (Image Credit: iStock)

Streamlined Genetic Testing Speeds Pediatric Immune Disorder Diagnosis

Children with genetic immune conditions can develop life-threatening illness, unusual infections, or autoimmune problems before the underlying cause is identified. More than 500 of these rare disorders... Read more

Immunology

view channel
Image: Acute myeloid leukemia is the first of several disease areas the collaborators plan to pursue together as part of efforts to advance precision diagnostics (Image Credit: Adobe Stock)

Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia

Acute myeloid leukemia (AML) is an aggressive blood cancer in which assessing disease burden after therapy can help guide clinical evaluation. Patients with measurable residual disease (MRD) after treatment... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.